Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.

3e ) showed lower pharmacokinetic exposure to LPV after administration of the combination SDN, but these differences did not reach statistical significance: average LPV/RTV C max =1,738 ng ml −1 and LPV/RTV SDN=1,194 ng ml −1 ( P =0.23); average LPV/RTV AUC=10,540 ng ml −1 h −1 and LPV/RTV SDN=8,423 ng ml −1 h −1 ( P =0.33).

also in 111,027 other papers